# Medgen Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medgen-life-sciences

- Industry: Materials
- Headquarters: Shenzhen, China
- Latest round: Series B (Jun 24, 2026)
- Investors on record: 4

## About

Founded in 2017 and based in Shenzhen, China, Shenzhen Medgen Life Sciences Co., Ltd., trading as Medgen Life Sciences, operates as a biomaterial manufacturing company that focuses on providing regenerative repair materials. It was recognized as the National High-tech Enterprise. The company has applied for 61 patents, with 12 software copyrights. In June 2026, it raised tens of millions of CNY in series B funding led by Shenzhen strategic emerging industries Investment, with participation from Jolmo Capital.

Medgen Life Sciences's main business is the research and development of regenerative repair materials. The main product is inducible bone repair materials. It has two major technology platforms: hydroxyapatite regenerative product transformation and biomedical collagen cross-linking technology. The products cover orthopedics, sports medicine, dentistry, medical beauty and other fields. The company is also engaged in the original research and development and production of orthopedic sports medicine products, the agency sales of anesthesiology and orthopedic products, and overseas biomedical investment.

The company generates revenue from the sales of regenerative repair materials and related service fees.

The company will use the series B funding for the research and development, production line upgrades, and market launch of materials related to serious medical and consumer medical applications, including hydroxyapatite, collagen, and decellularized ECM. Also, it will accelerate technological innovation and the launch of consumer medical products, and continuously invest in and upgrade its independent innovation and industrial transformation platform for regenerative medicine materials.

## Funding rounds

- Series B, Jun 24, 2026 — Jolmo Capital, Shenzhen strategic emerging industries Investment
- Series A, Jan 17, 2025 — YuanBio Venture
- Series A, Nov 29, 2024 — ALAN AMC

## Investors

- ALAN AMC (https://capitalatlas.ai/funds/alan-amc) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series B
- Shenzhen strategic emerging industries Investment — Series B